US FDA grants Lynparza Orphan Drug Designation for pancreatic cancer

Pressmeddelanden   •   Okt 16, 2018 08:01 CEST

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US today announced that they were granted orphan drug designation (ODD) by the US Food and Drug Administration (FDA) for Lynparza (olaparib) for the treatment of pancreatic cancer.

AstraZeneca presents advances in improving treatment options for ovarian and lung cancer patients at ESMO 2018

Pressmeddelanden   •   Okt 09, 2018 15:07 CEST

AstraZeneca and MedImmune, its global biologics research and development arm, will present 54 abstracts, including eight oral presentations and three late breakers, to the European Society of Medical Oncology (ESMO 2018) Congress in Munich, Germany, 19-23 October.

Christina Malmberg Hägerstrand ny presschef för AstraZeneca i Norden och Baltikum

Pressmeddelanden   •   Okt 05, 2018 09:07 CEST

AstraZeneca meddelar i dag att man har anställt Christina Malmberg Hägerstrand i en ny roll som presschef för bolaget i Norden och Baltikum. Hon börjar den 7 januari 2019 och kommer rapportera till Kommunikationsdirektör Jacob Lund.

Imfinzi is the first immunotherapy to demonstrate significant overall survival benefit in unresectable, Stage III lung cancer

Pressmeddelanden   •   Sep 25, 2018 14:21 CEST

Results from the Phase III PACIFIC trial were published simultaneously in the New England Journal of Medicine, showing Imfinzi (durvalumab) significantly improved OS, the second primary endpoint of the trial, compared to standard of care regardless of PD-L1 expression, reducing the risk of death by 32% (HR 0.68, 99.73% CI 0.47-0.997; p=0.0025).

Bydureon receives positive EU CHMP opinion for EXSCEL cardiovascular outcomes data

Pressmeddelanden   •   Sep 25, 2018 08:02 CEST

Elisabeth Björk, Vice President, Head of Cardiovascular, Renal and Metabolic Diseases, at AstraZeneca said: “We are pleased with this positive recommendation for Bydureon and what it means for patients with type-2 diabetes with a wide range of cardiovascular risk. Our pursuit of this label is based on our strong belief in the clinical value the EXSCEL data brings to physicians and patients.”

European Commission approves Imfinzi for locally-advanced, unresectable NSCLC

Pressmeddelanden   •   Sep 24, 2018 17:13 CEST

AstraZeneca and MedImmune, today announced that the European Commission has granted marketing authorisation for Imfinzi (durvalumab) as monotherapy for the treatment of locally-advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on ≥1% of tumour cells and whose disease has not progressed following platinum-based chemotherapy and radiation therapy (CRT).

Forxiga uppnådde ett positivt resultat i fas III-studien DECLARE TIMI 58, en stor kardiovaskulär studie med 17 000 patienter med typ 2-diabetes

Pressmeddelanden   •   Sep 24, 2018 08:03 CEST

AstraZeneca meddelade i dag positiva övergripande resultat från den kardiovaskulära fas III-studien DECLARE-TIMI 58 for Forxiga (dapagliflozin), den bredaste kardiovaskulära studien hittills för en SGLT2-hämmare.

AstraZeneca presents further data showing the interconnectivity between cardiovascular and renal risks in diabetes at EASD 2018

Pressmeddelanden   •   Sep 20, 2018 12:26 CEST

AstraZeneca and MedImmune, its global biologics research and development arm, will present more than 50 abstracts from the Company’s Cardiovascular, Renal & Metabolism (CVRM) therapy area at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Berlin, Germany, 1-5 October 2018.

Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma

Pressmeddelanden   •   Sep 18, 2018 08:04 CEST

AstraZeneca today announced results from the BORA Phase III extension trial evaluating the long-term safety and efficacy of Fasenra (benralizumab) as an add-on maintenance treatment in patients with severe eosinophilic asthma who had previously completed one of the two pivotal SIROCCO or CALIMA Phase III trials.

The Lancet Respiratory Medicine publishes first Phase III trial for PT010 triple combination therapy in moderate to very severe chronic obstructive pulmonary disease

Pressmeddelanden   •   Sep 16, 2018 17:29 CEST

Data from the KRONOS trial presented at the European Respiratory Society (ERS) International Congress 2018

Kontaktpersoner 2 kontaktpersoner

  • Presskontakt
  • Kommunikationsdirektör AstraZeneca Norden, Baltikum och ordförande Leif Johanssons kontor
  • jarycovnb.rblujrndcl@awkstzhraoxzeppneufcaga.cznomtr
  • 08 553 260 20 Mobil: 072 560 21 57

Om AstraZeneca

Om AstraZeneca

AstraZeneca är ett globalt, innovationsdrivet bioläkemedelsföretag med fokus på forskning, utveckling och marknadsföring av receptbelagda läkemedel, primärt för behandling av sjukdomar inom tre huvudsakliga terapiområden: cancer, kardiovaskulära sjukdomar, njursjukdomar och metabola sjukdomar och sjukdomar i andningsvägarna. Bolaget är också selektivt aktivt inom autoimmunitet, neurovetenskap och infektion. AstraZeneca bedriver verksamhet i över 100 länder och dess innovativa läkemedel används av miljontals patienter över hela världen. Mer information finns på: och